---
category: news
title: "BioXcel Therapeutics Announces Initiation of Phase 2 PLACIDITY Trial of BXCL501 for the Treatment of Delirium Related Agitation"
excerpt: "BioXcel Therapeutics, Inc. (\"BioXcel\" or the \"Company\") (NASDAQ:BTAI), a clinical-stage biopharmaceutical company"
publishedDateTime: 2021-02-25T12:00:00Z
originalUrl: "https://www.benzinga.com/pressreleases/21/02/g19848977/bioxcel-therapeutics-announces-initiation-of-phase-2-placidity-trial-of-bxcl501-for-the-treatment-"
webUrl: "https://www.benzinga.com/pressreleases/21/02/g19848977/bioxcel-therapeutics-announces-initiation-of-phase-2-placidity-trial-of-bxcl501-for-the-treatment-"
ampWebUrl: "https://amp.benzinga.com/amp/content/19848977"
cdnAmpWebUrl: "https://amp-benzinga-com.cdn.ampproject.org/c/s/amp.benzinga.com/amp/content/19848977"
type: article
quality: 0
heat: 0
published: false

provider:
  name: Benzinga.com
  domain: benzinga.com

topics:
  - AI in Healthcare
  - AI

secured: "/DX43PBTO+yK7O4x1Cbipo8XPFeAv7aeIVc098sGiFy5c3IeNLj0W4ahch6CwIRfN4oSs45eeafF5W5kO5bK5B9lourpOte0ka31tpgqM0hGXhrbmbHe2uphk0aav2hvU191SAQcbnqZAizVASRbp7KAKViR5sN7b4fzvoyyfTJ6ovQJqONwRMkvZsUmWLvHOpL5sh3f/cdRJ/xSZL+D45sW36AsUoXptbmnZHsG0LWcACRkjilqsITZUMX0B0JGgD/g4LknFrN8c/bsLi4+wRl/TbUilts0/COpoWwY9MsPVNCYJWJ4O31cfLNlY69rKxY9BTql460hdHsyD88LJq5xxco3HuJPyaxEFW0OscQ=;i92ZIC4dRT5JNRRiu9XAzA=="
---

